Today (2017 C.E. - 2025 C.E.)

This archive spans the years 2017 through 2025, a period marked by rapid advances in clean energy, medicine, technology, and social equity. It collects documented breakthroughs, policy wins, and scientific achievements from the present era. If you want evidence that progress is real and ongoing, this is where to look.

DNA, for article on artificial DNA cancer

In a world first, Japenese scientists use artificial DNA to kill cancer cells

Artificial DNA that turns cancer’s own biology against itself marks a genuine conceptual leap in oncology. Japanese researchers at the University of Tokyo engineered synthetic molecules that lie dormant until they detect a chemical cancer cells overproduce — then restructure themselves into a signal the immune system reads as a threat, destroying the tumor from within. Early tests spanned multiple cancer types, suggesting broad potential. This kind of precision — working with the body’s existing defenses rather than overwhelming them — is exactly the direction cancer medicine has been reaching toward, and this research moves that goal meaningfully closer.

3M mask, for article on PFAS phase-out

3M to end ‘forever chemicals’ output at cost of up to $2.3 bn

3M, one of the world’s largest makers of PFAS, will halt all production of these “forever chemicals” by the end of 2025, walking away from a business that brought in roughly $1.3 billion a year. The company expects to absorb up to $2.3 billion in pre-tax charges to exit — a sign it sees long-term liability as the bigger risk than lost revenue. The move follows mounting pressure from regulators, lawsuits, and a coalition of fund managers overseeing $8 trillion in assets who urged dozens of companies to phase PFAS out. Compounds linked to cancer, thyroid disruption, and developmental harm have turned up in drinking water and food supplies worldwide, and 3M’s deadline signals that the era of treating them as ordinary industrial inputs is drawing to a close.